Stephen N. Oesterle
CIK 1174532 · SrVP Medicine & Technology · last filed 2025-05-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.42M
Companies
5
Total Filings
36
Lifetime Open-Market Net
-$694.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BAX | Director | 35,847 | $24.61 | $882.0K | $0 | 10 | 2025-05-08 |
| Paragon 28, Inc. (FNA) Delisted | Director | 0 | $13.09 | $0 | $0 | 5 | 2025-04-21 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | Director | — | $22.47 | — | $0 | 5 | 2023-08-11 |
| HeartWare International, Inc. (HTWR) Delisted | Director | 0 | — | — | $32.2K | 4 | 2016-08-24 |
| MDT | SrVP Medicine & Technology | 52,209 | $87.01 | $4.54M | -$726.5K | 9 | 2009-08-05 |
Recent Filings · Page 2 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-27 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-05 | BAX | Grant (A) | +2,706 | $0 | EDGAR |
| 2021-12-03 | Paragon 28, Inc. (FNA) Delisted | Grant (A) | +7,031 | $0 | EDGAR |
| 2021-06-28 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-06 | BAX | Grant (A) | +2,230 | $0 | EDGAR |
| 2020-12-07 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-07 | BAX | Grant (A) | +2,197 | $0 | EDGAR |
| 2019-05-09 | BAX | Grant (A) | +2,412 | $0 | EDGAR |
| 2018-07-02 | — | Buy (P) | +16,359 | $25.0K | |
| 2018-05-18 | — | Grant (A) | — | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.